Retinal Drug Delivery technology
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
10
NCT06314217
Everads Injector in Suprachoroidal Administration of TA Suspension, for Treatment of Patients With DME
Phase: N/A
Role: Lead Sponsor
Start: Feb 18, 2024
Completion: Mar 26, 2025
Loading map...